Serum Interleukin (IL)-23 and IL-17 Profile in Inflammatory Bowel Disease (IBD) Patients Could Differentiate between Severe and Non-Severe Disease

Interleukin (IL)-17 and IL-23 are crucial for mediating gut mucosal inflammation in inflammatory bowel disease (IBD), which has led to new therapeutic strategies. We assessed the relevancy of IL-17 and IL-23 serum levels as potential biomarkers towards severe IBD discrimination and disease-related c...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Laura A. Lucaciu, Maria Ilieș, Ștefan C. Vesa, Radu Seicean, Shahida Din, Cristina Adela Iuga, Andrada Seicean
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	Crohn’s disease ulcerative colitis IBD severity interleukin-17 interleukin-23 biomarker Medicine R
Acceso en línea:	https://doaj.org/article/f1c8d307f70440e395d642eebdfde893
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f1c8d307f70440e395d642eebdfde893
record_format	dspace
spelling	oai:doaj.org-article:f1c8d307f70440e395d642eebdfde8932021-11-25T18:07:26ZSerum Interleukin (IL)-23 and IL-17 Profile in Inflammatory Bowel Disease (IBD) Patients Could Differentiate between Severe and Non-Severe Disease10.3390/jpm111111302075-4426https://doaj.org/article/f1c8d307f70440e395d642eebdfde8932021-11-01T00:00:00Zhttps://www.mdpi.com/2075-4426/11/11/1130https://doaj.org/toc/2075-4426Interleukin (IL)-17 and IL-23 are crucial for mediating gut mucosal inflammation in inflammatory bowel disease (IBD), which has led to new therapeutic strategies. We assessed the relevancy of IL-17 and IL-23 serum levels as potential biomarkers towards severe IBD discrimination and disease-related complications. Sixty-two patients diagnosed with Crohn’s disease (CD) and ulcerative colitis (UC) were included. Serum IL-17 and IL-23 were measured by sandwich enzyme-linked immunosorbent assays (ELISA). IL-23 and fecal calprotectin (FCal) were significantly higher in severe CD (<i>p</i> < 0.001) and UC (<i>p</i> < 0.001 and <i>p</i> = 0.001, respectively), compared to mild or moderate. Elevated C-reactive protein (CRP) was correlated with severe disease only in CD (<i>p</i> = 0.008), whereas for UC, disease severity was associated with increased IL-17 values (<i>p</i> < 0.001). Diagnostic role of IL-23 was superior to FCal in discriminating between severe and mild to moderate CD (<i>p</i> < 0.001). IL-23 levels were also significantly higher in CD patients with intestinal complications (<i>p</i> = 0.04). Both IL-17 and IL-23 correlate with IBD severity, and IL-23 might be a promising novel biomarker for severe CD. Identifying the dominant IL pathway involved in IBD severity could serve as guidance for clinical decision-making on biologic therapy.Laura A. LucaciuMaria IlieșȘtefan C. VesaRadu SeiceanShahida DinCristina Adela IugaAndrada SeiceanMDPI AGarticleCrohn’s diseaseulcerative colitisIBD severityinterleukin-17interleukin-23biomarkerMedicineRENJournal of Personalized Medicine, Vol 11, Iss 1130, p 1130 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Crohn’s disease ulcerative colitis IBD severity interleukin-17 interleukin-23 biomarker Medicine R
spellingShingle	Crohn’s disease ulcerative colitis IBD severity interleukin-17 interleukin-23 biomarker Medicine R Laura A. Lucaciu Maria Ilieș Ștefan C. Vesa Radu Seicean Shahida Din Cristina Adela Iuga Andrada Seicean Serum Interleukin (IL)-23 and IL-17 Profile in Inflammatory Bowel Disease (IBD) Patients Could Differentiate between Severe and Non-Severe Disease
description	Interleukin (IL)-17 and IL-23 are crucial for mediating gut mucosal inflammation in inflammatory bowel disease (IBD), which has led to new therapeutic strategies. We assessed the relevancy of IL-17 and IL-23 serum levels as potential biomarkers towards severe IBD discrimination and disease-related complications. Sixty-two patients diagnosed with Crohn’s disease (CD) and ulcerative colitis (UC) were included. Serum IL-17 and IL-23 were measured by sandwich enzyme-linked immunosorbent assays (ELISA). IL-23 and fecal calprotectin (FCal) were significantly higher in severe CD (<i>p</i> < 0.001) and UC (<i>p</i> < 0.001 and <i>p</i> = 0.001, respectively), compared to mild or moderate. Elevated C-reactive protein (CRP) was correlated with severe disease only in CD (<i>p</i> = 0.008), whereas for UC, disease severity was associated with increased IL-17 values (<i>p</i> < 0.001). Diagnostic role of IL-23 was superior to FCal in discriminating between severe and mild to moderate CD (<i>p</i> < 0.001). IL-23 levels were also significantly higher in CD patients with intestinal complications (<i>p</i> = 0.04). Both IL-17 and IL-23 correlate with IBD severity, and IL-23 might be a promising novel biomarker for severe CD. Identifying the dominant IL pathway involved in IBD severity could serve as guidance for clinical decision-making on biologic therapy.
format	article
author	Laura A. Lucaciu Maria Ilieș Ștefan C. Vesa Radu Seicean Shahida Din Cristina Adela Iuga Andrada Seicean
author_facet	Laura A. Lucaciu Maria Ilieș Ștefan C. Vesa Radu Seicean Shahida Din Cristina Adela Iuga Andrada Seicean
author_sort	Laura A. Lucaciu
title	Serum Interleukin (IL)-23 and IL-17 Profile in Inflammatory Bowel Disease (IBD) Patients Could Differentiate between Severe and Non-Severe Disease
title_short	Serum Interleukin (IL)-23 and IL-17 Profile in Inflammatory Bowel Disease (IBD) Patients Could Differentiate between Severe and Non-Severe Disease
title_full	Serum Interleukin (IL)-23 and IL-17 Profile in Inflammatory Bowel Disease (IBD) Patients Could Differentiate between Severe and Non-Severe Disease
title_fullStr	Serum Interleukin (IL)-23 and IL-17 Profile in Inflammatory Bowel Disease (IBD) Patients Could Differentiate between Severe and Non-Severe Disease
title_full_unstemmed	Serum Interleukin (IL)-23 and IL-17 Profile in Inflammatory Bowel Disease (IBD) Patients Could Differentiate between Severe and Non-Severe Disease
title_sort	serum interleukin (il)-23 and il-17 profile in inflammatory bowel disease (ibd) patients could differentiate between severe and non-severe disease
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/f1c8d307f70440e395d642eebdfde893
work_keys_str_mv	AT lauraalucaciu seruminterleukinil23andil17profileininflammatoryboweldiseaseibdpatientscoulddifferentiatebetweensevereandnonseveredisease AT mariailies seruminterleukinil23andil17profileininflammatoryboweldiseaseibdpatientscoulddifferentiatebetweensevereandnonseveredisease AT stefancvesa seruminterleukinil23andil17profileininflammatoryboweldiseaseibdpatientscoulddifferentiatebetweensevereandnonseveredisease AT raduseicean seruminterleukinil23andil17profileininflammatoryboweldiseaseibdpatientscoulddifferentiatebetweensevereandnonseveredisease AT shahidadin seruminterleukinil23andil17profileininflammatoryboweldiseaseibdpatientscoulddifferentiatebetweensevereandnonseveredisease AT cristinaadelaiuga seruminterleukinil23andil17profileininflammatoryboweldiseaseibdpatientscoulddifferentiatebetweensevereandnonseveredisease AT andradaseicean seruminterleukinil23andil17profileininflammatoryboweldiseaseibdpatientscoulddifferentiatebetweensevereandnonseveredisease
_version_	1718411655885357056

Serum Interleukin (IL)-23 and IL-17 Profile in Inflammatory Bowel Disease (IBD) Patients Could Differentiate between Severe and Non-Severe Disease

Ejemplares similares